<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000415</url>
  </required_header>
  <id_info>
    <org_study_id>TGOC-03</org_study_id>
    <secondary_id>ECPSU-522231012</secondary_id>
    <nct_id>NCT01000415</nct_id>
  </id_info>
  <brief_title>Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients</brief_title>
  <acronym>TGOCphaseIII</acronym>
  <official_title>Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thai Gynecologic Oncology Collaborative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council of Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Collaborative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thai Gynecologic Oncology Collaborative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to compare the effectiveness between the new strategy of treatment (given cis-platinum
           plus gemcitabine-neoadjuvant chemotherapy followed by surgery),and standard treatment
           (given cis-platinum/carboplatin during radiation-concurrent chemoradiation)in specific
           group of cervical cancer patients (stage Ib2-early IIb)

        -  to evaluate quality of life in both group of patients(standard treatment vs.experimental
           group)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to FIGO classification of cervical cancer, stage Ib2 was classified as clinically
      visible lesion more than 4.0 cm in greatest dimension and stage IIb was classified tumor
      invades parametrium must not to pelvic wall. These were the common stages in Thai cervical
      cancer patients,and made a troublesome effect to Thai women. According to this study,stage
      early IIb with 1/3 of parametrium involvement. Mostly these two stage was treated with
      concurrent chemoradiation, challenging the possibility of late sequelae of radiation effect.
      This specific group of patients can be avoid the referred side effect by using neoadjuvant
      chemotherapy followed by radical hysterectomy with pelvic lymphadenectomy and para-aortic
      node sampling in operable cases (at least partial response- PR) and concurrent chemoradiation
      (CCR) in inoperable cases (less than PR). Due to high risk type of these subspecific group,
      combination chemotherapy instead of single chemotherapy was used as CCR. However in operable
      cases with identified poor prognostic factor should be receive post operative radiation as
      the usual manner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival comparison between experimental treatment group and standard treatment group</measure>
    <time_frame>9 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing disease free survival between experimental treatment group and standard treatment group</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">824</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin plus gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy followed by surgery</intervention_name>
    <description>Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Cisplatin plus gemcitabine</arm_group_label>
    <other_name>Platinol,Platinol-AQ</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cervical cancer patients with FIGO stage Ib2-early IIb

          -  Pathological proven squamous cell carcinoma or adenocarcinoma or adenosquamous cell
             carcinoma

          -  ECOG performance status 0-1

          -  No previous treatment for cervical cancer

          -  Acceptable hematological,renal,liver function

        Exclusion Criteria:

          -  Previous history of cancer

          -  Underlying disease not fit for surgery

          -  Psychological problem

          -  Obvious pelvic/para-aortic node involvement

          -  Pregnancy

          -  HIV positive

          -  History of bowel obstruction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saibua B. Chichareon, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thai Gynecologic Oncology Collaborative Group (TGOC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saibua B. Chichareon, MD.</last_name>
    <phone>66 74 451201</phone>
    <email>saibua.c@psu.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chutaporn - Dampan, BSc</last_name>
    <phone>66 74 451201</phone>
    <email>djutapor@medicine.psu.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gynecologic Oncology Unit, Department of Obstertrics and Gynecology, Faculty of medicine, Prince of Songkla University</name>
      <address>
        <city>Hat-Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakchai - Buhachat, MD.</last_name>
      <phone>66 74 451201</phone>
      <email>brakchai@medicine.psu.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Chutaporn - Dampan, BSc.</last_name>
      <phone>66 74 451201</phone>
      <email>djutapor@medicine.psu.ac.th</email>
    </contact_backup>
    <investigator>
      <last_name>Rakchai - Buhachat, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Termrungruanglert W, Tresukosol D, Vasuratna A, Sittisomwong T, Lertkhachonsuk R, Sirisabya N. Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. Gynecol Oncol. 2005 May;97(2):576-81.</citation>
    <PMID>15863162</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>June 23, 2010</last_update_submitted>
  <last_update_submitted_qc>June 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2010</last_update_posted>
  <responsible_party>
    <organization>Thai Gynecologic Oncology Collaborative Group</organization>
  </responsible_party>
  <keyword>Stage Ib2-early IIb of cervical cancer</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Cisplatin plus gemcitabine</keyword>
  <keyword>Radical hysterectomy with pelvic lymphadenectomy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Stage Ib2-IIb of cervical cancer patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

